What is the current Price Target for the Prelude Therapeutics Inc stock?

The average Prelude Therapeutics Inc target price is $4.08. This is 164.94% higher than the current stock price. The highest price target is 240.91%, the lowest is 96.75%. 5 Analysts have issued a price target Prelude Therapeutics Inc 2026 .

How high will the Prelude Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Prelude Therapeutics Inc stock will rise. The performance of stocks, including the Prelude Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Prelude Therapeutics Inc stock today?

The performance of Prelude Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Prelude Therapeutics Inc stock fall?

The decline in Prelude Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Prelude Therapeutics Inc Forecast, price target & analysts

$1.54

11.59% today

Nasdaq, Dec 04, 10:00 pm CET

ISIN

US74065P1012

Symbol

PRLD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Prelude Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Prelude Therapeutics Inc Classifications & Recommendation:

Buy

80%

Hold

10%

Sell

10%

Prelude Therapeutics Inc Price Target

Target Price	$4.08
Price	$1.54
Potential	164.94% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Prelude Therapeutics Inc 2026 . The average Prelude Therapeutics Inc target price is $4.08. This is 164.94% register free of charge higher than the current stock price. The highest price target is $5.25 240.91% register free of charge , the lowest is $3.03 96.75% register free of charge .
	A rating was issued by 10 analysts: 8 Analysts recommend Prelude Therapeutics Inc to buy, 1 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Prelude Therapeutics Inc stock has an average upside potential 2026 of 164.94% register free of charge . Most analysts recommend the Prelude Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.68	-1.41
	16.83%	16.07%
P/E		negative

6 Analysts have issued a Prelude Therapeutics Inc forecast for earnings per share. The average Prelude Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.68	16.83%
2025	$-1.41 16.07% Unlock
2026	$-0.97 31.21% Unlock
2027	$-0.83 14.43% Unlock
2028	$-1.22 46.99% Unlock
2029	$-0.90 26.23% Unlock
2030	$-0.53 41.11% Unlock
2031	$-0.21 60.38% Unlock
2032	$0.15 171.43% Unlock

Current	-2.16	255.30%
2025	-0.98 54.55% Unlock
2026	-1.42 44.90% Unlock
2027	-1.65 16.20% Unlock

Prelude Therapeutics Inc...

Current Prelude Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 23 2025
JMP Securities	Locked ➜ Locked	Locked	Aug 18 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 05 2025
JMP Securities	Locked ➜ Locked	Locked	Apr 29 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 08 2025
Citizens Capital Markets	Locked ➜ Locked	Locked	Mar 12 2025
JMP Securities	Locked ➜ Locked	Locked	Dec 11 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 23 2025
Locked JMP Securities: Locked ➜ Locked	Aug 18 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	May 05 2025
Locked JMP Securities: Locked ➜ Locked	Apr 29 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 08 2025
Locked Citizens Capital Markets: Locked ➜ Locked	Mar 12 2025
Locked JMP Securities: Locked ➜ Locked	Dec 11 2024

Discover more stocks with a high price target

Netflix 1,273.57%

Adidas 48.28%

Coinbase Global, Inc. 47.34%

BioNTech SE - ADR 47.16%

Rheinmetall 45.71%

NIO ADR 42.52%

Deutsche Telekom 41.51%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now